Central to inflammatory bowel disease (IBD) pathogenesis is loss of mucosal barrier
function. Emerging evidence implicates extracellular adenosine signaling in attenuating
mucosal inflammation. We hypothesized that adenosine-mediated protection from intestinal
barrier dysfunction involves tissue-specific signaling through the A2B adenosine receptor
(Adora2b) at the intestinal mucosal surface. To address this hypothesis, we combined
pharmacologic studies and studies in mice with global or tissue-specific deletion of the …